ATE307595T1 - Verwendung von synthetischen fxr liganden zur behandlung von krankheiten die mit einem gestörten gleichgewicht des cholesterin-spiegels verbunden sind und von kolonkrebs - Google Patents

Verwendung von synthetischen fxr liganden zur behandlung von krankheiten die mit einem gestörten gleichgewicht des cholesterin-spiegels verbunden sind und von kolonkrebs

Info

Publication number
ATE307595T1
ATE307595T1 AT00941312T AT00941312T ATE307595T1 AT E307595 T1 ATE307595 T1 AT E307595T1 AT 00941312 T AT00941312 T AT 00941312T AT 00941312 T AT00941312 T AT 00941312T AT E307595 T1 ATE307595 T1 AT E307595T1
Authority
AT
Austria
Prior art keywords
imbalance
treatment
colon cancer
diseases associated
cholesterol levels
Prior art date
Application number
AT00941312T
Other languages
English (en)
Inventor
Barry M Forman
Richard L Beard
Roshantha A Chandraratna
Original Assignee
Allergan Inc
City Of Hope Nat Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, City Of Hope Nat Medical Ct filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE307595T1 publication Critical patent/ATE307595T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00941312T 1999-06-11 2000-06-09 Verwendung von synthetischen fxr liganden zur behandlung von krankheiten die mit einem gestörten gleichgewicht des cholesterin-spiegels verbunden sind und von kolonkrebs ATE307595T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13896899P 1999-06-11 1999-06-11
PCT/US2000/015912 WO2000076523A1 (en) 1999-06-11 2000-06-09 Methods for modulating fxr receptor activity

Publications (1)

Publication Number Publication Date
ATE307595T1 true ATE307595T1 (de) 2005-11-15

Family

ID=22484498

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941312T ATE307595T1 (de) 1999-06-11 2000-06-09 Verwendung von synthetischen fxr liganden zur behandlung von krankheiten die mit einem gestörten gleichgewicht des cholesterin-spiegels verbunden sind und von kolonkrebs

Country Status (10)

Country Link
EP (1) EP1185277B1 (de)
JP (1) JP2003501477A (de)
CN (1) CN1368884A (de)
AT (1) ATE307595T1 (de)
AU (1) AU768806B2 (de)
BR (1) BR0011743A (de)
CA (1) CA2377320A1 (de)
DE (1) DE60023493T2 (de)
HK (1) HK1047705A1 (de)
WO (1) WO2000076523A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132223A1 (en) * 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
US20020119958A1 (en) * 2001-02-13 2002-08-29 Shinichiro Tojo Therapeutic agent for hyperlipidemia
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
US20030144360A1 (en) * 2001-11-19 2003-07-31 Allergan Sales, Inc. Composition and method for modulating BAR/FXR receptor activity
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2003060078A2 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
US20050143449A1 (en) 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
ES2609395T5 (es) 2004-03-12 2021-08-06 Intercept Pharmaceuticals Inc Tratamiento de la fibrosis usando ligandos de Fxr
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
AU2008209566C1 (en) 2007-01-19 2013-02-14 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as TGR5 modulators and methods of use thereof
EP2324046B1 (de) 2008-07-30 2014-09-03 Intercept Pharmaceuticals, Inc. Tgr5-modulatoren und anwendungsverfahren dafür
SI2698375T1 (sl) 2008-11-19 2018-10-30 Intercept Pharmaceuticals, Inc. Modulatorji TGR5 in njihova uporaba
US20110257139A1 (en) 2008-12-19 2011-10-20 Royal College Of Surgeons In Ireland Treatment of diarrhoea
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
JP2015521621A (ja) 2012-06-19 2015-07-30 インターセプト ファーマシューティカルズ， インコーポレイテッド オベチコール酸の調製、使用および固体形態
ES2846183T3 (es) 2013-09-11 2021-07-28 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de la infección por el virus de la hepatitis B
JP2020515564A (ja) 2017-03-30 2020-05-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物
WO2021009332A1 (en) 2019-07-18 2021-01-21 Enyo Pharma Method for decreasing adverse-effects of interferon
JP2023510274A (ja) 2020-01-15 2023-03-13 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Ｄ型肝炎ウイルスによる感染を処置するためのｆｘｒアゴニストの使用
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588715A (en) * 1984-06-04 1986-05-13 Sandoz, Inc. Heptenoic acid derivatives
FR2707989B1 (fr) * 1993-07-22 1995-10-13 Pf Medicament Nouveaux dérivés de benzylamines silylées, leurs sels, leurs procédés de fabrication et les compositions pharmaceutiques les renfermant.

Also Published As

Publication number Publication date
CN1368884A (zh) 2002-09-11
EP1185277B1 (de) 2005-10-26
DE60023493T2 (de) 2006-07-20
EP1185277A1 (de) 2002-03-13
BR0011743A (pt) 2002-03-05
JP2003501477A (ja) 2003-01-14
DE60023493D1 (de) 2005-12-01
CA2377320A1 (en) 2000-12-21
AU5603200A (en) 2001-01-02
HK1047705A1 (zh) 2003-03-07
AU768806B2 (en) 2004-01-08
WO2000076523A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
ATE307595T1 (de) Verwendung von synthetischen fxr liganden zur behandlung von krankheiten die mit einem gestörten gleichgewicht des cholesterin-spiegels verbunden sind und von kolonkrebs
DE60033030D1 (de) Verwendung von gegen cd20 gerichteten antikörpern zur behandlung der graft versus host krankheit
DE69703649D1 (de) Behandlung von deagglomerierten teilchen mit plasmaaktivierter spezies
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE60032226D1 (de) Verfahren zur induktion von krebszellentod und tumorregression
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
ATE483976T1 (de) Gfats als modifikatoren des p53-wegs und verwendungsverfahren
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
DE60030277D1 (de) ANORDNUNGEN, SYSTEME UND VERFAHREN ZUR BEHANDLUNG VON BIOLOGISCHEN FLüSSIGKEITEN MIT LICHT
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE58902094D1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
ATE227127T1 (de) Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
DE69927876T2 (de) Metallocenverbindung, und Verfahren zur Herstellung von Polyolefine unter Verwendung dieser
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
DE69825440D1 (de) VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN
NO20010389D0 (no) Modulering av multippel linje-kinaseproteiner
ATE254128T1 (de) Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
WO2003043581A3 (en) Composition and method for modulating bar/fxr receptor activity
DE59002772D1 (de) Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.
ATE227130T1 (de) 5-alpha-pregnan-3-beta-ol-20-one 3-sulfate für di behandlung von tumoren und zns krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties